IP Library › Granted Patent US 10,213,544
Granted Patent B2
US 10,213,544 · App. 13/916,854 · Granted Feb 26, 2019

Methods for treating a suspension of mononuclear cells to facilitate extracorporeal photopheresis

Inventor: Katherine Radwanski (Des Plaines, IL)
Assignee: Fenwal, Inc.
A61M1/3681A61M1/3686A61M1/3692A61M1/3696A61M1/3496A61M1/3683A61M1/3693A61M2202/0439A61M2205/053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,213,544
App. No.
13/916,854
Granted
Feb 26, 2019
Kind
B2
Abstract

A method for performing a photopheresis procedure is provided comprising collecting MNCs in a suspension comprising RBCs and plasma and lysing the red blood cells in the solution, preferably by combining the suspension with a solution to cause lysis. In one example, the solution for causing lysis of the red blood cells comprises ammonium chloride, and the suspension including the ammonium chloride is incubated to cause lysing. After lysing, the suspension may be washed to remove plasma and hemoglobin freed by the lysis of the red blood cells, and an ultraviolet light activated substance is added to the suspension. The suspension is then irradiated with ultraviolet light.

Claims (27)

1. A method for performing extracorporeal photopheresis of mononuclear cells comprising:

withdrawing whole blood from a human subject;

introducing said whole blood into a separation chamber of an apheresis device;

separating mononuclear cells from red blood cells and plasma of said whole blood in said separation chamber;

collecting a suspension of mononuclear cells, said suspension further comprising at least residual red blood cells and residual plasma;

withdrawing said red blood cells and plasma that have been separated from said mononuclear cells from said separation chamber;

combining the collected suspension with a lysing solution;

incubating the suspension to lyse the residual red blood cells;

returning said mononuclear cell suspension to said separation chamber of said apheresis device after said withdrawing;

separating within said apheresis device said mononuclear cells from hemoglobin freed by the lysis of residual red blood cells, residual plasma and any lysing solution in said suspension;

removing from the suspension residual plasma, hemoglobin freed by the lysis of the red blood cells and any lysing solution by washing the suspension with saline by centrifugation;

adding an ultraviolet light activated agent to the saline-washed suspension;

irradiating the saline-washed suspension with ultraviolet light;

introducing said irradiated suspension into said separation chamber of said apheresis device;

concentrating the cells so as to have a smaller total volume of said suspension; and

reinfusing the suspension of concentrated cells having the smaller total volume into the human subject without increasing the total volume with additional plasma.

2. The method of claim 1 wherein the lysing agent does not substantially adversely affect the viability of the mononuclear cells in the suspension.

3. The method of claim 1 wherein the residual plasma and hemoglobin freed by the lysis of the red blood cells are removed substantially simultaneously.

4. The method of claim 1 in which the suspension is irradiated with ultraviolet light for five minutes or less.

5. The method of claim 1 in which the suspension is irradiated with UVA ultraviolet light.

6. The method of claim 1 in which the ultraviolet light activated substance comprises psoralen.

7. The method of claim 6 wherein the ultraviolet light activated substance comprises 8-methoxypsoralen.

8. The method of claim 1 comprising incubating said suspension with said lysing solution for about 3 to 20 minutes.

9. The method of claim 8 comprising incubating said suspension with said lysing solution for 10-15 minutes.

10. The method of claim 1 wherein the lysing solution comprises ammonium chloride.

11. The method of claim 10 wherein the ammonium chloride is added in an aqueous solution at predetermined concentration.

12. The method of claim 11 wherein the predetermined concentration is from about 100 mM to 200 mM.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2013
From: RADWANSKI, KATHERINE
To: FENWAL, INC.
Reel/Frame 030608/0198 →
Continuity (1)
Related Publication 20140370491A1 · Dec 18, 2014
Cited By (1)
US 12,558,469